Benjamin Machinas Beneski's most recent trade in Allogene Therapeutics Inc was a trade of 2,867 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on March 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 31 Mar 2026 | 2,867 | 195,338 (0%) | 0% | 2.5 | 7,168 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 2.47 per share. | 16 Mar 2026 | 4,835 | 198,205 (0%) | 0% | 2.5 | 11,942 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 02 Mar 2026 | 7,132 | 203,040 (0%) | 0% | 2.6 | 18,543 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 373,757 | 373,757 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 105,720 | 105,720 | - | - | Restricted Stock Unit | |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 1.73 per share. | 02 Feb 2026 | 7,549 | 210,172 (0%) | 0% | 1.7 | 13,060 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 1.22 per share. | 17 Nov 2025 | 786 | 217,721 (0%) | 0% | 1.2 | 959 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 14 Mar 2025 | 5,488 | 218,507 (0%) | 0% | 2.0 | 10,839 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 112,339 | 112,339 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 31,755 | 223,995 (0%) | 0% | 0 | Common Stock |